FIELD: biotechnology.
SUBSTANCE: present invention relates to lipophilic nanoparticles carrying matrix RNA with an open reading frame of bound nucleosides coding human interleukin-12 (IL12), its functional fragments and fusion proteins, including IL12.
EFFECT: invention can be used in medical practice to produce a drug applicable in therapy of various tumor diseases.
142 cl, 38 dwg, 17 ex, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| COMPOSITIONS AND METHODS OF ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF ENCODING RIBONUCLEIC ACIDS | 2019 |
|
RU2803294C2 |
| POLYNUCLEOTIDES ENCODING RELAXIN | 2017 |
|
RU2795683C2 |
| ARTIFICIAL NUCLEIC ACID MOLECULES | 2013 |
|
RU2651498C2 |
| RNA STRUCTURES AND APPLICATION THEREOF | 2021 |
|
RU2838444C1 |
| METHODS AND MEANS OF INCREASING PRODUCTIVITY OF RNA | 2015 |
|
RU2738753C2 |
| VACCINES BASED ON NUCLEIC ACIDS | 2015 |
|
RU2746406C2 |
| NEW MINIMUM UTR SEQUENCES | 2017 |
|
RU2759737C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| TREATING DISEASES ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY SUPPRESSION OF NATURAL ANTISENSE VEGF TRANSCRIPT | 2009 |
|
RU2569182C2 |
Authors
Dates
2022-03-30—Published
2017-05-18—Filed